Madrigal Pharmaceuticals, Inc. [MDGL]

Source: 

Company Overview

Madrigal Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company pursuing novel therapeutics for nonalcoholic steatohepatitis, or NASH. Our lead product candidate, resmetirom, is a proprietary, liver-directed, selective thyroid hormone receptor-  , or THR-  , agonist being developed as a once-daily oral pill for the treatment of NASH.